ARTICLE | Clinical News
Arbaclofen placarbil: Completed Phase III enrollment
April 15, 2013 7:00 AM UTC
XenoPort disclosed in its 4Q12 earnings that it completed enrollment in a double-blind, placebo-controlled, U.S. Phase III trial evaluating twice-daily 15, 30 and 45 mg arbaclofen placarbil for 13 wee...